Article

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

2021-08-31

Abstract excerpt

Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19, and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab),...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1bdc1bba-887d-536c-babf-7b8c50d87d2a
DOI: 10.1101/2021.08.30.21262666

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humansDOI 10.1101/2021.08.30.21262666Read

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsSemantic proximity Read

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinSemantic proximity Read

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal AntibodiesSemantic proximity Read

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody CocktailSemantic proximity Read

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsSemantic proximity Read

Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2Semantic proximity Read

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainSemantic proximity Read

Broadly neutralizing antibodies against COVID-19Semantic proximity Read